This increased risk of side effects has led investigators to explore the possibility to stop immunosuppressives (IS) (mostly AZA) in patients in remission on combination therapy. In the IMID study, 18 Crohn's disease (CD) patients in clinical remission for at least 6 months after starting IFX combined with IS were randomised to continue or interrupt IS, while they received scheduled IFX maintenance therapy for 104 weeks. In both arms, a similar proportion of patients needed a change in IFX dosing interval or stopped IFX therapy. However, at the end of the study, median CRP level was significantly higher and TLI significantly lower in the group of patients who discontinued IS. In another study, AZA withdrawal in CD patients in clinical remission under combination therapy was associated with a high risk of relapse in patients in whom the duration of combination therapy was less than 27 months. 
| PATIENTS AND METHODS

| Study design
This was a prospective, single-centre, randomised and interventional study including adult (≥ 18 years old) IBD patients with an established diagnosis of CD or ulcerative colitis (UC) treated in the Gastroenterology department of Saint Etienne University Hospital between July 2010 and September 2014. All IBD patients treated for at least 1 year with the combination therapy IFX-AZA and na€ ıve to AZA and IFX prior to the onset of this combination and with durable remission for at least 6 months were eligible. CD patients with mainly perianal location, stoma, penetrating phenotype and postoperative setting were excluded. UC patients treated for previous acute severe UC or for proctitis were also excluded. In addition, we excluded patients with thiopurine methyltransferase (TPMT) deficiency (one or two mutations after genotyping of TPMT), patients under mesalazine (mesalamine) or allopurinol and pregnant women.
At inclusion, patients had to be in remission for at least 6 months defined for CD by a Crohn's Disease Activity Index (CDAI)
< 150 points with faecal calprotectin levels < 250 lg/g of stools and
for UC by a total Mayo score < 3 points with endoscopic Mayo subscore 0-1 and stool blood subscore 0. 
| Study objectives
The primary aim of the study was to assess the percentage of failure during follow-up defined as the occurrence of a clinical relapse (CDAI>220 with a delta CDAI>70 from the previous assessment for CD, and total Mayo score>5 points with endoscopic Mayo subscore>1 for UC) and/or need to change the original therapeutic regimen because of adverse events or drug intolerance. The secondary aims were to assess the percentage of patients with an unfavourable evolution of IFX PK during follow-up defined as TLI<1 lg/mL or undetectable levels of IFX with or without positive ATI, and to determine the associated level of 6-TGN related to unfavourable evolution of IFX PK. In CD patients, C reactive protein (CRP) and
faecal calprotectin were measured at baseline and at the end of follow-up or time to failure. 62.5-100). The flowchart of the study is described in the Figure 1 .
| Statistical analysis
After randomisation, there were no losses from follow-up, three patients refused the allocated treatment and were excluded (1 and 2 patients in groups AZA down and AZA stopped, respectively). 
| Therapeutic failure during follow-up
| Evolution of infliximab pharmacokinetics during follow-up
In group AZA steady (no change in treatment after the inclusion), the median TLI were similar at the time of inclusion and at the end Endoscopic F I G U R E 3 Infliximab pharmacokinetics (IFX PK) in the three groups of patients. A, Evolution of trough levels of infliximab (TLI) during follow-up. B, Percentage of patients with an unfavourable evolution of IFX PK during follow-up since this PK profile has been associated with better outcomes in the long-term. [23] [24] [25] [26] [27] [28] Our data are in accordance with the IMID study. 18 In this openlabel randomised controlled trial, Van Assche et al. 18 assessed the influence of IS discontinuation in patients in steroid free remission under combination therapy for at least 6 months. Although a similar proportion of patients needed a change in IFX dosing interval or stopped IFX therapy, stopping IS resulted in a gradual decrease in TLI over time and more patients had undetectable TLI at later time points and developed ATI (12.5% vs 5.0%). More recently, the same group studied retrospectively 117 CD patients in durable remission after at least 6 months (median 13 months) of combination treatment who stopped their IS (85 thiopurines, 32 methotrexate). 22 Thirty-eight per cent of patients experienced a disease flare during the study period (median 29 months) and 12% of patients with detectable TLI at the time of immunomodulator withdrawal developed undetectable TLI during follow-up. Patients with a TLI>5 lg/ mL at time of IS withdrawal were the best candidates for discontinuation. 22 In our study, the percentage of treatment failure after stopping AZA was 31% during follow-up and 42% of patients developed TLI<1 lg/mL. Six patients who stopped AZA presented TLI>5 lg/mL at the inclusion and none presented failure or unfavourable IFX PK 1 year later.
Conversely, reduction in AZA dose by half was not associated with an increased risk of failure at 1 year, whereas two cases of myelotoxicity occurred in the group of patients with full dose of AZA. A halved dose of AZA was not associated with an unfavourable evolution of IFX PK and TLI remained stable during follow-up.
In our study, the optimal value of 6-TGN to predict unfavour- thiopurines, and high 6-TGN levels were found to be a risk factor in this patient population. 31 These results indicate that high 6-TGN levels may lead to DNA damage and contribute to promoting carcinogenesis in these patients. In a recent paper, a population-based cohort study was conducted in 4131 adult Australian with liver, heart and lung transplant recipients. 32 Higher mean daily doses (>1.3 mg/kg/day) of AZA were associated with increased risk of both early and late non-Hodgkin lymphoma. In our study, the mean AZA dose in patients of group AZA down receiving a halved dose was 1.2 mg/kg/day.
Our study presents some limitations. First, we acknowledge that the most important limitation of this study is related to a lack of study power. Indeed, we were unable to include the total number of patients initially estimated as necessary to test our hypothesis (102 patients). Therefore, we cannot exclude that the number of failure which is higher in the group of patients stopping AZA (given the borderline significant P-value of .09 between AZA down and AZA stopped and P-value of .12 between AZA steady and AZA stopped)
could be significant with more included patients. Second, we included patients with a normal metabolism of AZA, thus excluding patients with TPMT deficiency. Finally, this was an uncontrolled study. Our study also has several strengths. It is a prospective study with a standardised follow-up and all data on 6-TGN levels and IFX PK could be collected. Also, we used some objective signs of inflammation to define treatment failure.
In conclusion, in IBD patients in durable remission under combination therapy, AZA dose reduction, but not withdrawal of AZA, appears to be as effective as the maintenance of AZA at the usual dose of 2-2.5 mg/kg/day. Our results warrant therefore to be replicated in a larger cohort. A threshold of 6-TGN<105 pmoles/8.10 8 RBC was associated with an unfavourable evolution of IFX pharmacokinetics and should be used to guide decision-making in clinical practice. Whether halving the dose of AZA in this patient population will improve the long-term safety profile of combination therapy will require further investigation.
